A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Related articles:
Related suggestion:
China's central bank adds liquidity via reverse reposStone carvings found inside cave of China's Longmen GrottoesDamian Lillard sets Bucks' postseason mark with 35 points in opening half vs PacersEurope warming twice as fast as other continents, report saysOil consumption back to 2019 levelsGlobal exhibitors seek opportunities at consumer expo in HainanDirect flights resume between Chengdu, AucklandHow Phish is using the Las Vegas Sphere's technologyThe easily missed detail in the photos of Queen Mary's childrenNorth Korea has fired multiple missiles into the ocean, South Korea says
3.2181s , 6497.7109375 kb
Copyright © 2024 Powered by Colon cancer blood test offers new screening option ,Culture Curves news portal